TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase I trial studies the side effects and best dose of TAK-243 in treating patients with acute myeloid leukemia or myelodysplastic syndromes with increased blasts that has come back (relapsed) or that is not responding to treatment (refractory). TAK-243 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony rodzaj nowotworu krwi (białaczka AML lub zespół mielodysplastyczny MDS) według wytycznych WHO
- •Choroba powróciła po wcześniejszym leczeniu lub nie reaguje na leczenie
- •Dla białaczki: co najmniej 5% zmienonych komórek w szpiku kostnym po 2 kursach intensywnej chemioterapii lub 2 cyklach nowszych leków
- •Dla zespołów mielodysplastycznych: co najmniej 5% zmienonych komórek w szpiku kostnym po 4 cyklach terapii lub 2 kursach chemioterapii
- •Brak dostępu do innych zatwierdonych leków, które byłyby lepsze dla pacjenta
- •Ogólny stan zdrowia pacjenta pozwala na uczestnictwo w badaniu
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 27, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (5)
Moffitt Cancer Center
Tampa, United States
Northwestern University
Chicago, United States
Ohio State University Comprehensive Cancer Center
Columbus, United States
VCU Massey Comprehensive Cancer Center
Richmond, United States
University Health Network-Princess Margaret Hospital
Toronto, Canada
Trial contact
Site Public Contact
Jeffrey E. Lancet
PRINCIPAL_INVESTIGATOR
Site Public Contact
Himachandana Atluri
PRINCIPAL_INVESTIGATOR
Site Public Contact
Shivani Handa
PRINCIPAL_INVESTIGATOR
Site Public Contact
Keri R. Maher
PRINCIPAL_INVESTIGATOR
Site Public Contact
Guillaume Richard-Carpentier
PRINCIPAL_INVESTIGATOR
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/28/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.